WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL by Richard Lafayette, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Jonathan Barratt

Get full text

WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

The role of complement C3 deposition in ANCA-associated glomerulonephritis: a registry-based study of clinical, histopathological, and prognostic insights by Sami Uzun, Ebru Gok Oguz, Abdülmecit Yıldız, Ulver Derici, Emre Cankaya, Gulizar Sahin, Erhan Tatar, Garip Şahin, Mevlüt Tamer Dinçer, Necmi Eren, Kenan Turgutalp, Taner Baştürk, Melike Betül Öğütmen, Mehmet Tanrısev, Sim Kutlay, Murvet Yilmaz, Meltem Gürsu, Zülfükar Yılmaz, Zeki Toprak, Onur Tunca, Şebnem Karakan, Ece Ük, Belda Dursun, Mahmud İslam, Dilek Torun, Cuma Bulent Gul, Bulent Kaya, Bülent Altun, Abdulkadir Çelik, İdris Şahin, Serap Yadigar, Dilek Gibyeli Genek, Mehmet Deniz Ayli, Saide Elif Güllülü Boz, Omer Faruk Akcay, Meryem Keleş, Savaş Öztürk

Get full text